Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Profit After Tax (2018 - 2025)

Inmune Bio (INMB) has disclosed Profit After Tax for 8 consecutive years, with -$5.2 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 43.25% to -$5.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$45.9 million through Dec 2025, down 9.07% year-over-year, with the annual reading at -$45.9 million for FY2025, 9.07% down from the prior year.
  • Profit After Tax hit -$5.2 million in Q4 2025 for Inmune Bio, up from -$6.5 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$4.6 million in Q1 2021 to a low of -$24.5 million in Q2 2025.
  • Historically, Profit After Tax has averaged -$8.8 million across 5 years, with a median of -$8.1 million in 2022.
  • Biggest five-year swings in Profit After Tax: plummeted 215.7% in 2021 and later surged 46.48% in 2025.
  • Year by year, Profit After Tax stood at -$9.7 million in 2021, then soared by 39.69% to -$5.8 million in 2022, then crashed by 44.01% to -$8.4 million in 2023, then dropped by 9.74% to -$9.2 million in 2024, then surged by 43.25% to -$5.2 million in 2025.
  • Business Quant data shows Profit After Tax for INMB at -$5.2 million in Q4 2025, -$6.5 million in Q3 2025, and -$24.5 million in Q2 2025.